Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech, a US-based member of Roche Group, has released ICON7 Phase III study results, which demonstrated that Avastin (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening, compared to chemotherapy alone.
Subscribe to our email newsletter
Genentech’s ICON7 study is a multicenter, randomised, open-label, Phase III study in 1,528 women with previously untreated epithelial ovarian, primary peritoneal or fallopian tube carcinoma.
The primary endpoint of the study is progression-free survival (PFS) as assessed by trial investigators. Secondary endpoints of the study include overall survival, response rate, duration of response, quality of life and safety.
Hal Barron, executive vice president of global development and chief medical officer at Genentech, said: “It is encouraging that a second Phase III study showed that Avastin in combination with chemotherapy followed by the continued use of Avastin alone helped women live longer without their disease getting worse.”
Genentech has received sponsorship from the Medical Research Council (MRC) for the ICON7 study in the UK, led by the MRC Clinical Trials Unit and conducted through an international network of researchers in the Gynecologic Cancer InterGroup (GCIG).